BioSpace News Archive

Project focused on characterizing and assessing particle and chemical emissions from 3D printers

The Parker Institute for Cancer Immunotherapy (PICI) announced today that John Connolly, Ph.D., has been named chief scientific officer (CSO). In this role, Connolly will design and execute PICI’s overall research strategy in close collaboration with the institute’s leadership team, center directors and scientific steering committee.

In lieu of an in-person update to the media, Dr. Theresa Tam, Canada’s Chief Public Health Officer, issued the following statement.

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its second quarter 2020 financial results on Thursday, August 6, 2020, after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 4:30 p.m. ET to discuss the company’s results in greater detail. The conference call is being webcast and can be accessed from the Clovis Oncology website at www.clovison

Research Database to Quantify Impact of Potential COVID-19 Treatments, with Results from Over 500 Clinical Trials and Observational Studies Over the Next Three Months

Mr. Clancy brings significant strategic, financial and operational leadership experience in the biotechnology and pharmaceutical industry

Scientific Industries, Inc. (OTCQB:SCND), July 23, 2020 - Scientific Industries, Inc. announced the appointment of Reinhard Vogt to the Board of Directors and the resignation of Mr. James S. Segasture. Mr. John Moore, the Chairman of the Board, stated that the Company was extremely grateful for Mr. Segasture’s dedicated service to the Company as a Director since 1991 and wishes him well in his retirement.

BOSTON, MA / ACCESSWIRE / July 23, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin; technology platform for respiratory diseases, cancer, and other indications, today announced that the Company will present phase 1 dose-escalation monotherapy and combination with atezolizumab data for PRS-343

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced the completion of enrollment in its controlled, Phase 2 trial of relacorilant combined with nab-paclitaxel (Abraxane ® ) in patients with metastatic, platinum-resistant ovarian cancer. “We achieved

Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time on Wednesday, August 5, 2020.